Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy

Intensive Care Medicine

Volumn 42, Issue 12, 2016, Pages 1958-1969

  Perner, Anders ^a   Gordon, Anthony C ^b   De Backer, Daniel ^c   Dimopoulos, George ^d   Russell, James A ^e   Lipman, Jeffrey ^f   Jensen, Jens Ulrik ^a   Myburgh, John ^g   Singer, Mervyn ^h   Bellomo, Rinaldo ⁱ   Walsh, Timothy ^j  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

Antibiotic; Critical care; Intensive care; Sepsis; Shock

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; HYPERTENSIVE FACTOR; INOTROPIC AGENT; ANTIINFECTIVE AGENT; CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT;

ANTIBIOTIC THERAPY; BLOOD TRANSFUSION; FLUID RESUSCITATION; HEMODYNAMICS; HUMAN; LEUKOCYTE COUNT; MICROORGANISM DETECTION; OUTCOME ASSESSMENT; RESUSCITATION; REVIEW; RISK FACTOR; SEPSIS; TREATMENT INDICATION; BLOOD; FLUID THERAPY; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; MICROBIOLOGY; MORTALITY; STANDARDS;

ANTI-BACTERIAL AGENTS; BIOMARKERS; CARDIOTONIC AGENTS; CRITICAL CARE; FLUID THERAPY; HEMODYNAMICS; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; RESUSCITATION; SEPSIS; VASOCONSTRICTOR AGENTS;

EID: 84989159417     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4577-z     Document Type: Review

References (97)

1. Fleischmann C, Scherag A, Adhikari NK et al (2015) Assessment of Global Incidence and Mortality of Hospital-treated sepsis—current estimates and limitations. Am J Respir Crit Care Med. doi:10.1164/rccm.201504-0781OC
2. Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538. doi:10.1007/s00134-003-1662-x
3. Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655
4. Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810. doi:10.1001/jama.2016.0287
5. Gaieski DF, Edwards JM, Kallan MJ, Carr BG (2013) Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41:1167–1174. doi:10.1097/CCM.0b013e31827c09f8
6. Kaukonen K-M, Bailey M, Suzuki S et al (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:1308–1316. doi:10.1001/jama.2014.2637
7. Rhee C, Gohil S, Klompas M (2014) Regulatory mandates for sepsis care—reasons for caution. N Engl J Med 370:1673–1676. doi:10.1056/NEJMp1400276
8. Kaukonen K-M, Bailey M, Pilcher D et al (2015) Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372:1629–1638. doi:10.1056/NEJMoa1415236
9. Shankar-Hari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:775–787. doi:10.1001/jama.2016.0289
10. Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:762–774. doi:10.1001/jama.2016.0288
11. Ferreira FL, Bota DP, Bross A et al (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758
12. Tang BMP, Eslick GD, Craig JC, McLean AS (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–217. doi:10.1016/S1473-3099(07)70052-X
13. Travaglino F, De Berardinis B, Magrini L et al (2012) Utility of procalcitonin (PCT) and mid regional pro-adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis 12:184. doi:10.1186/1471-2334-12-184
14. Burillo A, Bouza E (2014) Use of rapid diagnostic techniques in ICU patients with infections. BMC Infect Dis 14:593. doi:10.1186/s12879-014-0593-1
15. Liesenfeld O, Lehman L, Hunfeld K-P, Kost G (2014) Molecular diagnosis of sepsis: new aspects and recent developments. Eur J Microbiol Immunol 4:1–25. doi:10.1556/EuJMI.4.2014.1.1
16. Leli C, Cenci E, Cardaccia A et al (2013) Rapid identification of bacterial and fungal pathogens from positive blood cultures by MALDI-TOF MS. Int J Med Microbiol 303:205–209. doi:10.1016/j.ijmm.2013.03.002
17. Vincent J-L, Brealey D, Libert N et al (2015) Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections. Crit Care Med 43:2283–2291. doi:10.1097/CCM.0000000000001249
18. Salimnia H, Fairfax MR, Lephart PR et al (2016) Evaluation of the filmarray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol 54:687–698. doi:10.1128/JCM.01679-15
19. Cercenado E, Marín M, Burillo A et al (2012) Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI assay. J Clin Microbiol 50:4095–4097. doi:10.1128/JCM.02409-12
20. Sinclair A, Xie X, Teltscher M, Dendukuri N (2013) Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 51:2303–2310. doi:10.1128/JCM.00137-13
21. de Ory F, Minguito T (2009) Comparison of five commercial assays for the detection of Legionella pneumophila antigens in urine. Enferm Infecc Microbiol Clín 27:81–84. doi:10.1016/j.eimc.2008.03.002
22. Emmadi R, Boonyaratanakornkit JB, Selvarangan R et al (2011) Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn 13:583–604. doi:10.1016/j.jmoldx.2011.05.011
23. Schelenz S, Barnes RA, Barton RC et al (2015) British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis 15:461–474. doi:10.1016/S1473-3099(15)70006-X
24. Bouadma L, Luyt C-E, Tubach F et al (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474. doi:10.1016/S0140-6736(09)61879-1
25. de Jong E, van Oers JA, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827. doi:10.1016/S1473-3099(16)00053-0
26. Jensen JU, Hein L, Lundgren B et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–2058. doi:10.1097/CCM.0b013e31821e8791
27. Sweeney TE, Shidham A, Wong HR, Khatri P (2015) A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. Sci Transl Med 7:287ra71. doi:10.1126/scitranslmed.aaa5993
28. McHugh L, Seldon TA, Brandon RA et al (2015) A molecular host response assay to discriminate between sepsis and infection-negative systemic inflammation in critically ill patients: discovery and validation in independent cohorts. PLoS Med 12:e1001916. doi:10.1371/journal.pmed.1001916
29. Garcia-Simon M, Morales JM, Modesto-Alapont V et al (2015) Prognosis biomarkers of Severe Sepsis and Septic Shock by 1H nmr urine metabolomics in the intensive care unit. Plos ONE 10:e0140993. doi:10.1371/journal.pone.0140993
30. Lin S-M, Wang Y-M, Lin H-C et al (2008) Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 36:683–689. doi:10.1097/CCM.0B013E31816537D8
31. Ware LB, Koyama T, Zhao Z et al (2013) Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 17:R253. doi:10.1186/cc13080
32. Madonna R, Jiang J, Geng Y-J (2012) Attenuated expression of gelsolin in association with induction of aquaporin-1 and nitric oxide synthase in dysfunctional hearts of aging mice exposed to endotoxin. Int J Immunopathol Pharmacol 25:911–922
33. Armand-Lefèvre L, Angebault C, Barbier F et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488–1495. doi:10.1128/AAC.01823-12
34. Rubinstein E, Keynan Y (2013) Short-course therapy for severe infections. Int J Antimicrob Agents 42(Suppl):S22–S24. doi:10.1016/j.ijantimicag.2013.04.013
35. Klompas M (2012) What can we learn from international ventilator-associated pneumonia rates? Crit Care Med 40:3303–3304. doi:10.1097/CCM.0b013e31826bf3a5
36. Sugianto TD, Chan H-K (2015) Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives. Expert Opin Drug Deliv. doi:10.1517/17425247.2015.1078309
37. Wong G, Brinkman A, Benefield RJ et al (2014) An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69:1416–1423. doi:10.1093/jac/dkt523
38. Bergen P, Bulitta J, Kirkpatrick C et al (2016) Effect of different renal function on anti-bacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow fibre infection model and mechanism-based modelling. J Antimicrob Chemother. doi:10.1093/jac/dkw153
39. 2 relationship. Intensive Care Med 40:1643–1648. doi:10.1007/s00134-014-3472-8
40. Ronco JJ, Fenwick JC, Tweeddale MG et al (1993) Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA 270:1724–1730
41. Asfar P, Meziani F, Hamel J-F et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593. doi:10.1056/NEJMoa1312173
42. Angus DC, Barnato AE, Bell D et al (2015) A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 41:1549–1560. doi:10.1007/s00134-015-3822-1
43. De Backer D, Vincent J-L (2016) Early goal-directed therapy: do we have a definitive answer? Intensive Care Med 42:1048–1050. doi:10.1007/s00134-016-4295-6
44. Ospina-Tascón GA, Umaña M, Bermúdez WF et al (2015) Can venous-to-arterial carbon dioxide differences reflect microcirculatory alterations in patients with septic shock? Intensive Care Med. doi:10.1007/s00134-015-4133-2
45. Vallée F, Vallet B, Mathe O et al (2008) Central venous-to-arterial carbon dioxide difference: an additional target for goal-directed therapy in septic shock? Intensive Care Med 34:2218–2225. doi:10.1007/s00134-008-1199-0
46. Ospina-Tascón GA, Bautista-Rincón DF, Umaña M et al (2013) Persistently high venous-to-arterial carbon dioxide differences during early resuscitation are associated with poor outcomes in septic shock. Crit Care 17:R294. doi:10.1186/cc13160
47. Monnet X, Julien F, Ait-Hamou N et al (2013) Lactate and venoarterial carbon dioxide difference/arterial-venous oxygen difference ratio, but not central venous oxygen saturation, predict increase in oxygen consumption in fluid responders. Crit Care Med 41:1412–1420. doi:10.1097/CCM.0b013e318275cece
48. De Backer D, Creteur J, Preiser J-C et al (2002) Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166:98–104
49. De Backer D, Donadello K, Sakr Y et al (2013) Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med 41:791–799. doi:10.1097/CCM.0b013e3182742e8b
50. Perner A, Haase N, Guttormsen AB et al (2012) Hydroxyethyl starch 130/0.42 vs. Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134. doi:10.1056/NEJMoa1204242
51. Myburgh JA, Finfer S, Bellomo R et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911. doi:10.1056/NEJMoa1209759
52. Haase N, Perner A, Hennings LI et al (2013) Hydroxyethyl starch 130/0.38-0.45 vs. crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
53. Perner A, Junttila E, Haney M et al (2015) Scandinavian clinical practice guideline on choice of fluid in resuscitation of critically ill patients with acute circulatory failure. Acta Anaesthesiol Scand 59:274–285. doi:10.1111/aas.12429
54. Cecconi M, Hofer C, Teboul J-L et al (2015) Fluid challenges in intensive care: the FENICE study: a global inception cohort study. Intensive Care Med 41:1529–1537. doi:10.1007/s00134-015-3850-x
55. SAFE Study Investigators, Finfer S, McEvoy S et al (2011) Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 37:86–96. doi:10.1007/s00134-010-2039-6
56. Caironi P, Tognoni G, Masson S et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421. doi:10.1056/NEJMoa1305727
57. Patel A, Laffan MA, Waheed U, Brett SJ (2014) Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ 349:g4561
58. Yunos NM, Bellomo R, Glassford N et al (2015) Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis. Intensive Care Med 41:257–264. doi:10.1007/s00134-014-3593-0
59. Young P, Bailey M, Beasley R et al (2015) Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the split randomized clinical trial. JAMA 314:1701–1710. doi:10.1001/jama.2015.12334
60. Boyd JH, Forbes J, Nakada T et al (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265. doi:10.1097/CCM.0b013e3181feeb15
61. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228. doi:10.1007/s00134-012-2769-8
62. Maybauer MO, Maybauer DM, Enkhbaatar P et al (2014) The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 42:e525–e533. doi:10.1097/CCM.0000000000000300
63. Walkey AJ, Wiener RS, Ghobrial JM et al (2011) Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 306:2248–2254. doi:10.1001/jama.2011.1615
64. Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124. doi:10.1056/NEJMoa071366
65. Linder A, Lee T, Fisher J et al (2016) Short-term organ dysfunction is associated with long-term (10-year) mortality of septic shock. Crit Care Med 44:e728–e736. doi:10.1097/CCM.0000000000001843
66. Chawla LS, Busse L, Brasha-Mitchell E et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 18:534. doi:10.1186/s13054-014-0534-9
67. Kirov MY, Evgenov OV, Evgenov NV et al (2001) Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 29:1860–1867
68. Donati A, Conti G, Loggi S et al (2002) Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 30:2271–2277. doi:10.1097/01.CCM.0000029185.70149.5F
69. Wang Z, Lambden S, Taylor V et al (2014) Pharmacological inhibition of DDAH1 improves survival, haemodynamics and organ function in experimental septic shock. Biochem J 460:309–316. doi:10.1042/BJ20131666
70. Russell JA (2016) Genomics and pharmacogenomics of sepsis: so close and yet so far. Crit Care 20:185. doi:10.1186/s13054-016-1374-6
71. Nakada T-A, Russell JA, Boyd JH et al (2010) beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 181:143–149. doi:10.1164/rccm.200903-0332OC
72. Nakada T, Russell JA, Wellman H et al (2011) Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 139:1042–1049. doi:10.1378/chest.10-2517
73. Lasker MV, Leventhal SM, Lim D et al (2015) Hyperactive human glucocorticoid receptor isoforms and their implications for the stress response. Shock 43:228–232. doi:10.1097/SHK.0000000000000289
74. Bentzer P, Fjell C, Walley KR et al (2016) Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive Care Med. doi:10.1007/s00134-016-4338-z
75. Nakada T, Russell JA, Boyd JH et al (2011) Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 39:1641–1648. doi:10.1097/CCM.0b013e318218665a
76. Health C for D and R In Vitro Diagnostics—Companion Diagnostics. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm. Accessed 14 Sep 2016
77. Research C for DE and Genomics—Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed 14 Sep 2016
78. Walley KR, Thain KR, Russell JA et al (2014) PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 6:258ra143. doi:10.1126/scitranslmed.3008782
79. Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691. doi:10.1001/jama.2013.278477
80. Shahul S, Gulati G, Hacker MR et al (2015) Detection of myocardial dysfunction in septic shock: a speckle-tracking echocardiography study. Anesth Analg 121:1547–1554. doi:10.1213/ANE.0000000000000943
81. Vieillard-Baron A, Slama M, Cholley B et al (2008) Echocardiography in the intensive care unit: from evolution to revolution? Intensive Care Med 34:243–249. doi:10.1007/s00134-007-0923-5
82. Hayes MA, Timmins AC, Yau EH et al (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330:1717–1722. doi:10.1056/NEJM199406163302404
83. Schmittinger CA, Torgersen C, Luckner G et al (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:950–958. doi:10.1007/s00134-012-2531-2
84. Wang Q, Yokoo H, Takashina M et al (2015) Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages. Crit Care Med 43:e508–e520. doi:10.1097/CCM.0000000000001269
85. Koster G, Wetterslev J, Gluud C et al (2015) Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 41:203–221. doi:10.1007/s00134-014-3604-1
86. Zangrillo A, Putzu A, Monaco F et al (2015) Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials. J Crit Care. doi:10.1016/j.jcrc.2015.05.017
87. Orme RML, Perkins GD, McAuley DF et al (2014) An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials 15:199. doi:10.1186/1745-6215-15-199
88. Perner A, Myburgh J (2015) Ten “short-lived” beliefs in intensive care medicine. Intensive Care Med 41:1703–1706. doi:10.1007/s00134-015-3733-1
89. Ibrahim-Zada I, Rhee P, Gomez CT et al (2014) Inhibition of sepsis-induced inflammatory response by β1-adrenergic antagonists. J Trauma Acute Care Surg 76:320–327. doi:10.1097/TA.0000000000000113
90. Ruchala P, Nemeth E (2014) The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci 35:155–161. doi:10.1016/j.tips.2014.01.004
91. Pieracci FM, Stovall RT, Jaouen B et al (2014) A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness. Crit Care Med 42:2048–2057. doi:10.1097/CCM.0000000000000408
92. Rohde JM, Dimcheff DE, Blumberg N et al (2014) Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 311:1317–1326. doi:10.1001/jama.2014.2726
93. Lacroix J, Hébert PC, Fergusson DA et al (2015) Age of transfused blood in critically ill adults. N Engl J Med 372:1410–1418. doi:10.1056/NEJMoa1500704
94. Steiner ME, Ness PM, Assmann SF et al (2015) Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 372:1419–1429. doi:10.1056/NEJMoa1414219
95. Holst LB, Petersen MW, Haase N et al (2015) Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ 350:h1354
96. Holst LB, Haase N, Wetterslev J et al (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371:1381–1391. doi:10.1056/NEJMoa1406617
97. Docherty AB, O’Donnell R, Brunskill S et al (2016) Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ 352:i1351